<DOC>
	<DOCNO>NCT00213044</DOCNO>
	<brief_summary>Randomized , control , double-blinded , cross-over trial 60 HIV-infected woman recruit general medical clinic , family planning clinic , groups/organizations work person live AIDS assess product safety , effect genital tract HIV shedding , product acceptability vaginal use Carraguard gel among HIV-infected woman . Women abstinent seroconcordant relationship one partner study period .</brief_summary>
	<brief_title>A Randomized , Controlled , Cross-Over Trial Safety Vaginal Use Carraguard HIV-Infected Women</brief_title>
	<detailed_description>Carraguardâ„¢ ( PC-515 ) , Population Council 's lead candidate microbicide , test randomize , control trial Chiang Rai , northern Thailand . Safety daily product use determine symptom irritation , effect vaginal flora , vaginal epithelial disruption determine naked eye inspection ( Day 7 Day 14 arm ) colposcopic inspection ( Day 7 ) , adverse effect , may include UTI unforeseen problem ( Day 7 Day 14 ) . Genital tract HIV measure use sample collect CVL ( Day 7 Day 14 arm ) vaginal swab ( Day 7 Day 14 ) . Product acceptability assess interview-administered questionnaire study arm first follow-up visit ( Day 7 arm ) , use product daily 7 day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Age 1850 year Plan stay Chiang Rai area least four month HIVinfected , confirm Elisa Western Blot test Either 1 ) current sex partner plan abstinent study duration , 2 ) one , HIVinfected sexual partner1 18 year old willing give inform consent confirmatory HIV test participant=s enrollment study . Women steady partner/husband see study period sexually active require bring partner clinic HIV testing informed consent . Willing able give inform consent Willing able comply study protocol , include test HIV undergo repeat pelvic colposcopic examination Willing male partner ask informed consent expose study product Regular menstrual cycle ( define occur every 35 week , last 35 day ) prior 3 month ; amenorrhea use depoprovera , participant must report history vaginal bleeding previous 3 month CD4 count &lt; 5002 Not currently take antiretroviral medications3 Documented Class I Class II ( `` atypical cell see , usually cause inflammation '' ) pap smear screening study participation In good health determine medical history , physical examination result laboratory screening test , discretion clinical staff Able achieve score 80 % good truefalse test key study concept . If woman score less 80 % first time take test , may repeat test least one day later CD4 count &lt; 50 Pregnancy desire become pregnant next 34 month Delivery , miscarriage , abortion within six week prior study enrollment History surgery external genitalia , vagina cervix month prior study enrollment Existence clinically detectable genital abnormality , specifically warts congenital abnormality History nonmenstrual vaginal bleeding intercourse past one month Current use tampon , diaphragm , sponge , douche , intravaginal product . Women willing abstain use product study include study . Concurrent participation another trial vaginal product History sensitivity allergy latex product ( include glove ) Presence epithelial disruption labium genital mucosa visible naked eye enrollment1 Positive test gonorrhea , chlamydial infection , trichomoniasis , evidence untreated syphilis ( see section 5.19 ) . Participants positive test must treat negative test cure eligible enrollment.1 Positive test candidiasis bacterial vaginosis ( BV ) symptoms vaginitis . Women may enrol treatment asymptomatic negative test . Asymptomatic participant positive test candidiasis BV may enrol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Microbicides</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>HIV-positive woman</keyword>
	<keyword>safety</keyword>
	<keyword>carrageenan</keyword>
	<keyword>HIV</keyword>
</DOC>